13 results about "Human gut" patented technology

The invention discloses a specific amplification primer pair for human intestinal archaea flora 16S rRNA amplicon sequencing and application of the specific amplification primer pair, and belongs to the technical field of biology.The primer pair is designed for 16S rRNA high-throughput sequencing and can specifically amplify human intestinal archaea, the length of an amplification product is about 385bp, and the amplification product covers a V4-V5 variable region of a 16S rRNA gene; the invention also optimizes amplification conditions of the primer pair, and experimental results show that the primer pair is superior to a conventional universal primer for bacteria and archaea in the aspect of amplifying species diversity and species abundance of the intestinal archaea, and a standardized method is provided for efficient and accurate amplification of intestinal archaea florae.

The invention belongs to the technical field of bioengineering, and discloses a specific identification primer and method for lactobacillus curvatus in human intestinal tracts and application. The identification primer comprises an upstream primer COG3825F1 and a downstream primer COG3825R1, the nucleotide sequence of the upstream primer COG3825F1 is 5 '-GTCACAACAAGACCGATTT-3', and the nucleotide sequence of the downstream primer COG3825R1 is 5 '-CTGTTTCTACAACTTGTGCT-3', and the nucleotide sequence of the upstream primer COG3825F1 and the nucleotide sequence of the downstream primer COG3825R1 are 5 '-GTCACAACAAGACCGATTT-3'. The specific COG3825 gene of the lactobacillus flexus is screened to serve as a target sequence design primer, and PCR, gel electrophoresis and qPCR verification show that the primer has extremely high specificity and sensitivity and can accurately distinguish the lactobacillus flexus from the related lactobacillus and other common intestinal bacteria under the complex micro-ecological background of the human intestinal tract; the identification method based on the primer is easy and convenient to operate and accurate in result, qualitative and quantitative detection of the lactobacillus brevis in human intestinal samples, food samples and other environment samples can be achieved, and important technical support is provided for related research, application development and micro-ecological monitoring of the lactobacillus brevis.

This invention discloses a method for constructing a multi-target amplicon abundance standard for microorganisms and its application, belonging to the fields of molecular biology detection and microbiome analysis. This standard material screens sequences of common human gut microbiota strains, designs and adds universal primers, and obtains 14 DNA fragments of different lengths through gene synthesis, cloning, and purification, which are then mixed according to a preset abundance. It retains natural characteristics such as primer binding sites and GC content, and can systematically correct technical deviations in amplicon sequencing, solving the problem of species abundance distortion. This standard material functions as both a non-homologous internal reference and a homologous external reference, and can be used for laboratory proficiency testing, reagent kit performance evaluation, and cross-platform data calibration, promoting the leap from relative qualitative to absolute quantitative research in microbiome studies and providing metrological support for the standardization and precision of detection results.

The application discloses a directional screening method of a human intestinal Lacticaseibacillus paracasei strain, and comprises the following steps: step 1, preparation of directional solid and liquid culture media; step 2, weighing of feces and culture by using the culture media in step 1; and step 3, screening of the Lacticaseibacillus paracasei strain from the bacterial liquid obtained after enrichment in step 2, so as to obtain the Lacticaseibacillus paracasei strain. The directional screening method is developed according to the growth characteristics of intestinal flora and the physiological and biochemical properties of the Lacticaseibacillus paracasei, so that the efficiency and quality of the strain screening are higher.

The present invention relates to an in-vitro model of thehuman gut microbiome, the model comprising a culture of the gut microbiome, wherein the model has a cumulative enzymatic coverage of more than 85% of the gut microbiome of a healthy human. The model facilitates metabolic modeling and enables a better understanding of the structure and function of the human gut microbiome as well as of modifications of xenobiotics by intrinsic gut microbiota, such as biotransformation and bioaccumulation. It can further be used to study the effects of variations in nutritional conditions. Importantly, the invention can also be used for diagnosing a disease, such as a gastrointestinal disorder,a proliferative disease, a metabolic disorder, a cardiovascular disease, an immunological disease, and an infectious disease.

This invention discloses the application of a morel mycelium extract, belonging to the field of natural products. The morel mycelium extract is mainly composed of α-glucan, with a weight-average molecular weight of 10,000 kDa to 15,000 kDa, a number-average molecular weight of 10,000 kDa to 12,000 kDa, a polydispersity index of 1.0-1.3, and a glucose molar percentage of not less than 99%. The preparation method includes ultrasonic-assisted extraction, alcohol precipitation, enzymatic hydrolysis, dialysis, and ethanol gradient purification. The morel mycelium extract of this invention has the effect of regulating intestinal flora, specifically by improving… Enterococcus , Citrobacter and Bacillus Species abundance of genera, decreased Clostridium and Ruminococcus It has a high species abundance and is more easily utilized by the human gut microbiota than inulin, rapidly decomposing to produce short-chain fatty acids.

This application provides a strain of *Bifidobacterium pseudolongum* capable of converting *Poria cocos* oligosaccharides into prebiotics and its applications, belonging to the field of microbial technology. The *Bifidobacterium pseudolongum* strain provided in this application (… Bifidobacterium pseudolongum subsp. globosum L10, deposited at the Guangdong Provincial Center for Microbial Culture Collection (GDMCC No. 67277) on November 12, 2025, is a bacterium that can utilize poria cocos oligosaccharides derived from poria cocos acidic polysaccharides for proliferation and decompose and transform the poria cocos oligosaccharides. The resulting substances can be utilized and proliferated by probiotics in the human gut, thereby regulating the balance of the human gut microbiota and improving the body's immunity. It also provides a new way of utilizing poria cocos acidic polysaccharides and improves their availability.

The invention provides a novel gene editing protein Cas12a-X, a mutant Cas12a-X1 of the novel gene editing protein Cas12a-X and application of the mutant Cas12a-X1. According to the invention, a new gene editing protein Cas12a-X is explored from a metagenome of human intestinal microorganisms, and the homology of the gene editing protein Cas12a-X and common LbCas12a is 48%. Through the guidance of crRNA, the novel gene editor shows remarkable in-vitro and in-vivo editing activity, the editing efficiency is equivalent to that of LbCas12a, and the application value is high. Based on the structure and functional characteristics of a wild type Cas12a-X protein, mutation is carried out on amino acid sites of a key structural domain of the wild type Cas12a-X protein to obtain a Cas12a-X1 three-protruding variant. In-vivo experiments prove that the gene editing efficiency of the mutant is improved by at least 1.2 times compared with that of wild type Cas12a-X. The application range of the CRISPR-Cas12a system is expanded, and a new tool is provided for the fields of precision medicine, disease treatment, variety improvement and the like.

The present technology relates generally to compositions and the methods of preparations thereof for genetically engineering gut-microbiota in vitro. The present technology further relates to uses of compositions in vivo.

The present invention aims to provide an intestinal environment improving agent that can improve the human gut microbiota. [Solution] Bofu-tsusho-san extract is useful as an intestinal environment improving agent used to increase the proportion of Bifidobacteria and / or Lactobacillus in the human intestinal flora.

The invention discloses application of a morchella mycelium extract, and belongs to the field of natural products. The morchella mycelium extract mainly comprises alpha-glucan, the weight-average molecular weight of the morchella mycelium extract ranges from 10000 kDa to 15000 kDa, the number-average molecular weight of the morchella mycelium extract ranges from 10000 kDa to 12000 kDa, the polydispersity index of the morchella mycelium extract ranges from 1.0 to 1.3, and the molar percentage of glucose is not lower than 99%. The preparation method comprises the steps of ultrasonic-assisted extraction, alcohol precipitation, enzymolysis, dialysis and ethanol gradient purification. The morchella mycelium extract disclosed by the invention has an effect of regulating intestinal flora, specifically, the morchella mycelium extract is used for improving the abundance of Enterococcus, Citrobacter and Bacillus species and reducing the abundance of Clostridium and Ruminococcus species, and compared with inulin, the morchella mycelium extract is more easily utilized by the intestinal flora of a human body and is quickly decomposed to generate short-chain fatty acid.

The present invention relates to an in-vitro model of the human gut microbiome, the model comprising a culture of the gut microbiome, wherein the model has a cumulative enzymatic coverage of more than 85% of the gut microbiome of a healthy human. The model facilitates metabolic modeling and enables a better understanding of the structure and function of the human gut microbiome as well as of modifications of xenobiotics by intrinsic gut microbiota, such as biotransformation and bioaccumulation. It can further be used to study the effects of variations in nutritional conditions. Importantly, the invention can also be used for diagnosing a disease, such as a gastrointestinal disorder, a proliferative disease, a metabolic disorder, a cardiovascular disease, an immunological disease, and an infectious disease.